Popular search terms:
Search Results Label
11 results found-
Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.
https://www.seqirus.us/expertise -
Our leadership team is composed of experienced professionals with deep scientific expertise and a shared commitment to public health. Meet them now.
https://www.seqirus.us/our-company/leadership -
Our leadership team is composed of experienced professionals with deep scientific expertise and a shared commitment to public health. Meet them now.
https://www.seqirus.us/our-company/leadership/gregg-sylvester -
Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.seqirus.us/our-company -
The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate
https://www.seqirus.us/news/the-university-of-queensland-cepi-and-csl-partner-on-covid-19-vaccine-candidate -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news/covid19-update -
Afluria QIV is produced by Seqirus Inc., a company with specific expertise in influenza vaccines.
https://www.seqirus.us/-/media/seqirus/pdfs/pregnancy-registry-documents/afluria-informed-consentv10sample.pdf -
Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season
https://www.seqirus.us/news/seqirus-is-first-to-market-with-shipment-of-seasonal-influenza-vaccines-for-2016-2017-season -
Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older
https://www.seqirus.us/news/be-fluent-partnership-shines-spotlight-on-importance-of-flu-prevention-in-seniors -
In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.
https://www.seqirus.us/news/seqirus-announces-next-major-advancement-in-cell-based-influenza-vaccine-technology